Evotec CEO Christian Wojczewski (L) and Halozyme CEO Helen Torley
Evotec gains on Halozyme's takeover proposal
Halozyme said Thursday post-market that it wants to buy Evotec for €11 per share in cash, giving the struggling drug discoverer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
